New Drug Better Than tPA?
Researchers from The Ohio State University College of Medicine and The Ohio State University Wexner Medical Center have developed a new stroke therapy that, when tested in mice and dogs, has proven highly preferable to the standard of care therapy now offered to patients suffering a stroke.
DTRI-03 works this way: Thrombosis, or a blood clot, is the leading cause of disability and death in the western world. Current agents used to treat these conditions are limited by a short therapeutic window, irreversibility, and major risk of hemorrhage. To overcome these limitations, we developed a novel drug, called DTRI-031, that selectively binds and inhibits platelet adhesion and arterial blood clots while enabling rapid reversal of this antiplatelet activity by an antidote oligonucleotide.
"We have shown that our drug, DTRI-03, is completely reversible and opens up a blocked blood vessel better than the 'clot buster' drug called tPA, which is the only drug used in stroke today. This outcome may result in the first new drug in more than 20 years to treat patients with stroke," said lead researcher Dr. Shahid Nimjee, an endovascular neurosurgeon at Ohio State Wexner Medical Center's Comprehensive Stroke Center." |